



IPO INSIGHTS

KRONOX

Kronox Lab Sciences Limited

Kronox Lab Sciences limited

Issue Dates - Opens: 03-06-2024 | Closes: 05-06-2024

IPO Note	<ol style="list-style-type: none"> Kronox Lab Sciences Limited is a manufacturer of high-purity speciality fine chemicals for diverse end-user industries. The Company's High Purity Specialty Fine Chemicals are used in various applications such as manufacturing APIs, pharmaceutical formulations, scientific research, nutraceuticals, biotech applications, agrochemical formulations, personal care products, metal refineries, and animal health products.
Rating	★ ★ ★ (Good)

IPO SNAPSHOT

Issue Size	₹130.15 Crores
Issue Type	Book Built Issue IPO
Fresh Issue	-
Offer for Sale	₹130.15 Crores
Face Value Per Share	₹10
Price Band Per Share	₹129 to ₹136
Minimum Lot Size	110 shares
Listing On	BSE, NSE
Registrar to the Issue	Kfin Technologies Limited

IPO SNAPSHOT – Kronox Lab Sciences Limited

About the Company

- Incorporated in 2008
- The Company offers a wide range of over 185 products, including phosphate, sulphate, acetate, chloride, citrate, nitrates, nitrites, carbonate, EDTA derivatives, hydroxide, succinate, gluconate, and others.
- The Company's High Purity Specialty Fine Chemicals are used in various applications such as manufacturing APIs, pharmaceutical formulations, scientific research, nutraceuticals, biotech applications, agrochemical formulations, personal care products, metal refineries, and animal health products.
- The Company offers a wide range of over 185 products, including phosphate, sulphate, acetate, chloride, citrate, nitrates, nitrites, carbonate, EDTA derivatives, hydroxide, succinate, gluconate, and others. These products are supplied to customers in India and more than 20 countries worldwide.
- We manufacture High Purity Speciality Fine Chemicals of various grades in particle sizes ranging from 10 mesh to 100 mesh. They believe that their focus on product development, diversity in product offerings, meeting quality standards and customer specifications and continuous process improvement has led to repeat orders from our customers over the years.
- Their products are manufactured in accordance with industry standards like IP, BP, EP, JP, USP, FCC, LR, AR, GR and ACS in addition to custom manufacturing specifications, which differ from the industry standards, required by our customers in select cases

Competitive Strengths

- Wide range of products finding applications in diversified end user industries
- Long standing relationships with customers
- High entry and exit barriers due to long customer approval cycles and strict product standards and focus on R&D and Quality Control
- Zero debt company with strong and consistent financial performance
- Experienced Promoters and Senior Management with extensive domain knowledge

Financials (₹ in Crores)

Particulars	31-3-2021	31-3-2022	31-03-2023	Y-o-Y
Revenue	62.46	82.25	95.78	16%
EBITDA	14.80	19.70	21.99	12%
EBITDA Margin	23.7%	23.9%	23.0%	
PAT	9.73	13.62	16.62	22%
PAT Margin	15.6%	16.6%	17.4%	

Valuation

- Attributing Annualized FY23 Earnings asking P/E = 30.37

Peers

Company Name	P/E ratio
Tatva Chintan Pharma Chem Limited	55.67
Tanfac Industries Limited	35.10
Neogen Chemicals Limited	79.13
Sigachi Industries Limited	44.96
DMCC Speciality Chemical Limited	108.44

Note : P/E ratio is calculated as closing share price as on 31st May,2024.

Promoters

- Jogindersingh Jaswal
- Ketan Ramani
- Pritesh Ramani

Objects of the issue

- The Company will not receive any proceeds from the Offer for Sale

DISCLAIMER

The information provided by or in this newsletter is generally from the press reports, electronic media, research websites and other media. It also includes information from interviews conducted, analysis, views expressed by our research team. Investors should not rely solely on the information contained in this publication and must make their own investment decision based on their specific objectives and financial positions and using such independent advisor as they believe necessary. The material and the information provided herein are not and should not be construed as an advice to buy or sell any of the securities named in this newsletter. SIHL may or may not hold positions in any of the securities named in this newsletter as a part of its business. Past performance is not necessarily an indication of future performance. SIHL does not assure for accuracy and correctness of information of reports in this newsletter.

